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Summary The aim of this investigation was to assess the pharmacokinetics of sulfa­
methoxazole (S) with its hydroxy metabolites (SOH, N4SOH, N4OH) and 
N4-acetyl- (N4) and Ni-glucuronide (Sgluc) conjugates in 7 human volunteers 
after an oral dose of 800mg using a reversed phase gradient high-pressure liquid 
chromatography (HPLC) with UV detection. Sulfamethoxazole was rapidly and 
completely absorbed and metabolised to 5 metabolites. The plasma half-life (t1/,) 
of elimination varied for the parent drug and its metabolites between 9.7 and 15 
hours. The protein binding of S (67.2%) increased when the compound was acet­
yl ated (8 8%), and decreased when it was oxidised at the 5-position (40%). 
Glucuronidation at the N|-position reduced the protein binding to 20%. The main
metabolite in urine was N4 (43.5 ± 5.6%), followed by S (14.4 ± 3.4%).
The percentages o f the Sgluc (9.8 ± 2.6%), N4SOH (5.3 ± 1.0%), and SOH
(3.0 ± 1 .()%>) did not differ statistically (p = NS). Only 2 to 3% of the N-hydroxyl- 
amine metabolite (N4OH) was excreted. The renal clearance
176 ± 33 ml/min, SOH 96.1 ± 23.7 ml/min, N4SOH 51.2 ± 10.4 ml/min, N4 35.2
± 5.6 ml/min and S 2.7 ± 0.9 ml/min. The pharmacokinetic behaviour of the 
Ni-glucuronide was reported for the first time. If one of the metabolites is
nsible for the occurrence of side effects, then all metabolites must be in-
s were: ;
;d in this analysis.
The known metabolism o f sulfamethoxazole in­ fer the occurrence o f adverse effects with
volves acetylation and oxidation at the N4 nitrogen cotrimoxazole treatment for Pneumocystis carinii 
atom leading to N4-acetylsulfamethoxazole (N4 ) pneumonia in HIV-positive patients.Is ! I-Iydroxyl-
and NU-hydroxysulfamelhoxazole (N4 0 H )J 1-4 
The latter compound is thought to be responsible
ation also takes place at the C5 group, lead-
ing to 5-hydroxysulfamethoxazole (SOH) and N4-
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acetyl-5-hy droxysulfamethoxazole (N4SOH) J3,6‘1 Recently we investigated the pharmacokinetics
The existence of sulfamethoxazole-Ni-glucuron- of the N-hydroxylamine of sulfamethoxazole in 
ide (Sgluc) in urine has been described.^’6'10! The human volunteers by isocratic as well as gradient 
molecular structures of sulfamethoxazole and its high-pressure liquid chromatography (HPLC), and
metabolites are shown in figure 1. observed the presence of the Ni-glucuronide
Sulfamethoxazole is predominantly eliminated conjugate o f sulfamethoxazole.f151
by N4-acetylation, the metabolite being eliminated The pharmacokinetics for Ni-glucuronides of
by active tubular secretionJ3,11-141 The renal elim- sulfonamides have previously been described for
ination o f sulfamethoxazole occurs via the passive sulfadimedioxinej 16,171 sulfa-6-monomethoxineJ181
renal processes of glomerular filtration minus sulfamethomidineJ19i and sulfaphenazoW 2°J but
passive tubular reabsorption, implying that the re- not for sulfam ethoxazole. N i-glucuronides of
nal clearance depends primarily on protein binding sulfonamides can be measured well by direct gra-
and urine pH, and to a minor extent on urine flow. dient HPLC analysis.
With an acidic urine pH the renal clearance of The aim o f  this study was to investigate the
sulfamethoxazole is low (2.5 ml/min), and with an pharmacokinetics o f  sulfamethoxazole with its
alkaline urine pH it is high (25 ml/min)Ju ' 14^ hydroxy metabolites, and N4-acetyl- and Ni-glu-
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Fig. 2. Plasma concentration versus time curves of sulfamethoxazole (S), sulfamethoxazole-Ni-g!ucuronide (Sgluc), 
5-hydroxysulfamethoxazole (SOH), N-i-acetylsulfamethoxazole (N4) and N.racetyl-5-hydroxysulfamethoxazole (N4SOH) in a 
volunteer (no. 3) after a single oral dose of sulfamethoxazole 800mg. For reasons of clarity, only the renal excretion rate-time profile 
and cumulative amount excreted (% mol dose) of sulfamethoxazole are given.
Participants and Methods Sampling
Participants Blood samples were collected in heparinised
Eppendorf vessels (2ml) at regular time intervals over 
Seven human volunteers (4 males, 3 females; 2 days after administration by means of fingertip 
4 fast acetylators and 3 slow acetylators o f  sulfa- puncture with Monolet® lancets (Monoject, St
© Adis International Limited. All rights reserved. Clin. Drug Invest. 9(1) 1995
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Louis, USA). After centrifuging at 3000#, plasma 
samples were stored at -20°C pending analysis.
Urine was collected upon untimed voiding. The 
total time of sample collection was 96 hours. Three 
samples (7ml) of each void were stored at -20°C  
pending analysis.
Sample Treatment
Plasma samples (100|il) were deproteinised
with IOOjj.1 acetonitrile, centrifuged at 3000#, and
20)lX1 o f  the supernatant was injected onto the 
column.
Drug Analysis Urlne Somptes
For the m easurem ent o f N 4OH, urine was 
Sulfamethoxazole and all metabolites were an- centrifuged at 3000g, the supernatant was diluted
alysed by direct HPLC analysis as described in de­
tail elsewhere.!151
1:9 with 0.2 mol/L KH2PO4 buffer pH 5.0, and
20ul was injected onto the column.
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Fig. 3. Renal excretion rate-time profiles and cumulative amount excreted (% mol dose) of sulfamethoxazoie-Ni-glucuronide (Sgluc), 
5-hydroxysulfamethoxazole (SOH), N4-acetylsulfamethoxazole (N 4), N4-acetyl-5 -hydroxysulfamethoxazole (N4SOH), and 
N<rhydroxysulfamethoxazole (N4OH) in a volunteer (no. 3) after a single oral dose of sulfamethoxazole 800mg. For reasons of clarity, 
the renal excretion rate-time profile of sulfamethoxazole is omitted in this figure and is shown in figure 2 .
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Fig. 4. Plasma concentration versus time curves of sulfamethoxazole (S), sulfamethoxazole-Ni-glucuronide (Sgluc), 
5-hydroxysulfamethoxazole (SOH), NU-acetylsulfamethoxazole (N4) and N4-acetyl-5 -hydroxysulfamethoxazole (N4SOH) in a volun­
teer (no. 4) after a single oral dose of sulfamethoxazole 800mg. For reasons of clarity, only the renal excretion rate-time profile of 
sulfamethoxazole is given.
Protein Binding
The protein (in vitro)
For the measurement o f sulfamethoxazole and
the other metabolites, 50|il diethylamine was 
added to the urine sample of 7ml (pH 10) to in­
crease the solubility of all sulfonamides, centri­
fuged at 3000g, and thereafter the supernatant methoxazole and its metabolites was measured in
was diluted 1:9 with 0.2 m ol/L  K2PO4 buffer blank plasma samples by means of the Amicon 
pH 5-0. Micropartition system M P S-1 (Grace BV, Amicon
Division, Capelle aan de IJssel, The Netherlands). 
The average protein binding was calculated from 
4 spiked-plasma samples, equilibrated for 15 min-
Intraday-lnterday Coefficient of Variation
The intraday and interday coefficients of varia-
tion of sulfamethoxazole and its metabolites were utes at 37°C. Minimal drug binding to the filters
<5%.I,5I was observed.
© Adis Internationa! Limited. All rights reserved. Clin, Drug Invest, 9(1) 1995
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Table I. Pharmacokinetic parameters of sulfamethoxazole (S) after a single oral dose of 800mg to healthy volunteers (n = 7)
Parameter Mean ± SD
S p value0 N4 p valueb N4SOH p value0 Sgluc
.. ..  ^
p value SOH
Cmax (mg/L) 50.2 ± 9.6 <0.0001 8.3 ± 2.0 0.0093 0.56 ±0.14 0.77 ± 0.31 0.38 ±0.17
tiag (h) 0.29 ± 0.41 0.48 ± 0.49 1.11 ±0.89 1.21 ±1.00 0.74 ± 1.03
Wx (h) 1.0 ±0.8 <0.0001 6.9 ±1.7 0.0019 10.4 ±1.7 0.0020 5.5 ± 3.4 9.3 ±3.8
abs (h) 0.12 ±0.14 0.0146 2.3 ± 0.9 0.0163 4.5 ± 2.4 0.0117 1.3 ± 1.4 4.7 ± 5.0
tv2 (h) 9.7 ± 1.3 11.2 ± 1.7 11.1 ±3.3 0.0352 15.2 ± 5.3 9.5 ±1.7
MRT (h) 14.4 i  2.2 0.0044 19.8 + 2.9 0.0289 24.1 ±3.1 25,1 ±6.8 21.5 ±3.5
MRTi (h) 0 5.7 ± 1.9 10.1 ±3.0 9.6 ± 7.6 20.6 ±14.2
M RTij (h) 0 a 3.9 ± 1.9 e e
AUC (mg/L*h) 742. ± 201 <0.0001 198, ± 41 0.0052 20.3 ± 7.5 19.8 ±4.9 12.5 ±5.7
CU (L/h) 0.93 ± 0.24 0.0133 1,9 ± 0.3 2.5 ± 0.7 0.0002 4.9 ±1.7 4.8 ±2,0
V8S (L) 12.7 ±2.5 0.0537 30.3 ± 7.9 • 42.9 ± 19.0 0.0005 102.6 + 30.4 94.7 ± 53.4
% dose excreted' 14.4 ±3.4 <0.0001 43.5 ± 5,6 <0.0001 5.3 ±1.0 0.0091 9.8 ±2.6 0.0004 3.0 ± 1.0
CLr (ml/min) 2.7 ±0.9 <0.002 35.2 ± 5.6 51.2 + 10.4 <0.0001 176 ±33 <0.0001 96.1 ±23.7
a Difference between S and N4. 
b Difference between N4 and N4SOH. 
c Difference between N4SOH and Sgluc. 
d Difference between Sgluc and SOH. 
e Not stable in plasma.
f % dose excreted for sulfamethoxazole-N-hydroxylamine = 2.1 ± 0.9%.
Abbreviations: AUC = area under the concentration-time curve; C U  =  oral clearance; CLr = renal clearance; Cmax =  maximum plasma drug 
concentration; MRT = mean residence time; MRTj = intrinsic mean residence time (metabolite - parent); MRTy = intrinsic mean residence 
time (metabolite j * metabolite i); N4= IVacetylsulfamethoxazole; N4SOH = INU-acetyl-5-hydroxysulfamethoxazole; Sgluc = sulfamethoxazole- 
Nrgiucuronide; SOH = 5-hydroxysulfamethoxazoIe; tiag = lag time; tmax = time to reach maximum concentration; tv*. = half-life; t '.2 abs = 
absorption half-life; Vss = apparent volume of distribution at steady-state.
Drugs
Sulfamethoxazole and N4-ac e ty 1 s u If a-m e th ox- 
azole were obtained from Hoffmann-LaRoche
(Mijdrecht, The Netherlands). The metabolites 5- 
hydroxysulfamethoxazole, N4-acetyi- 5-hydroxy- 
sulfamethoxazole, and sulfamethoxazole- N j-gluc- 
uronide were isolated from human urine as 
described elsewhere J151 N4-hydroxysulfamethox- 
azole was synthesised by Synthon (Nijmegen, The 
Netherlands). All other reagents were of proanalysi 
quality and obtained from Merck (Darmstadt, 
Germany).
Pharmacokinetics
infinity (AUCo-°°) values were calculated using the 
linear trapezoidal rule with extrapolation to infin­
ity from C(last)/A,z:
MRT = AU MC/AUC = VSS/CL + l/k a + tiag;
t ' /■>z \ n 2 J \ z
where MRT is the mean residence time, AUMC is 
the area under the moment curve, Vss is the appar­
ent volume o f  distribution at steady-state, CL is the 
total body clearance, ka is the absorption rate con­
stant, tiag is the lag time and V/2z is the elimination 
half-life.
C L o , parent — F  • D/AUCO-00Curve fitting was carried out, and pharmacoki­
netic parameters were calculated using the
MediWare® computer package The area under where CL0,parent is the oral clearance o f the parent
the plasma concentration-time curve from zero to drug, and the bioavailability F taken as the total
<ù Adis international Limited, All rights reserved. Clin. Drug Invest. 9 (1) 1995
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percentage of parent drug and metabolites of the 
molar dose (umol) excreted in the urine.
Results
CLo.metaboIite — Fm • D / A U C q.oo
where CL0,metabolite is the oral clearance of the me­
tabolite, and the bioavailability of the metabolite 
Fm is approximately equal to the percentage of the 
molar dose excreted in the urine as metabolite.
Renal clearance CLr = mg excreted/AUCo-oo, 
which corresponds to the average renal clearance 
obtained from the renal excretion rate divided by 
the extrapolated plasma concentration at the mid­
point of the urine collection period (n = 5). For 
metabolites with a small AUCo-«., the average renal 
clearance was calculated.
M R T  — MRTabsorption +  MRTdisposition
with MRTabsorption «  MRTdisposition.
M R T i =  M R T  metabolite - M R T  parent
where M R T i is the intrinsic mean residence time, 
and
MRTjj — MRTmetabolite ij - MRTmetabolite KN4SOH-N4).
Statistical Analysis
Figure 2 shows an example o f plasma concen­
tration-time curves and figure 3 the corresponding
renal excretion rate-time of tl"-
methoxazole and its metabolites in one male vol-
t>6
a-
unteer (no. 3). In this particular volunteer, 
of the metabolites in plasma were slightly 
than that o f the parent drug. Figure 4 shows 
tical half-lives o f the parent drug and metabolites 
in the plasma concentration-time curves of 
methoxazole in another volunteer (no. 4).
Table I summarises the mean ± SD values of the 
measured pharmacokinetic parameters o f sulfa­
methoxazole in the volunteers.
The lag time indicates the length of time elapsed 
before the appearance o f a measurable plasma con­
centration of drug and metabolites. The average 
sequence o f appearance in the blood was sulfa­
methoxazole 0.29 ± 0.41 hours, N4 at 0.48 ±  0.49 
hours (p = NS), SOH at 0.74 ± 1.03 hours (p = NS), 
N4SOH at 1.11 ±  0.89 hours (p = 0.028), finally
followed by Sgluc at 1.21 ±  1.00 hour (p = 0.049; 
p values compared with sulfamethoxazole.
The time at which the maximum concentration 
(Cmax) was reached (tmax) was the shortest for the
parent drug (1.02 ± 0.84 hours), followed by that
for Sgluc at 5.5 ±  3.4 hours (p = 0.0024), N4 at 6.9
Regression lines, standard deviations, and anal- ±  1 -7 hours (pcO.GOO 1 ), SOH at 9.3 ±  3.8 hours
ysis of variance (ANOVA) were calculated accord- (P 0.0004) and N4SOH at 10.4 ± 1.7 hours
ing to standard statistical procedures.!23! Statisti- (pcO.OOOl; p v; 
cal significance was defined as p<0.05.
compared with tl**
Table II. In vitro protein binding of sulfamethoxazole and its metabolites
Compound Concentration (mg/L) Protein binding (%) CV (%)
Sulfamethoxazole 52,0 67.2 4.3
5-Hydroxysulfamethoxazole 9.9 40.3 5.4
Sulfamethoxazole-N 1 -gl ucu ronide 10.1 26.7 1.1
N4-acetylsulfamethoxazole 9.6 88.1 4.7
N4-acetyl-5-hydroxysulfamethoxazole 11.6 69,5 15
N/phydroxysulfamethoxazole 8 il a
a Not stable in plasma.
Abbreviation: CV = coefficient of variation.
o  Adis International Limited. All rights reserved. Clin. Drug Invest. 9(1) 1995
Table III. Apparent and true renal clearance values of sulfamethoxazole and its metabolites
Compound C L r ,appararti
(ml/min)
Protein binding 
(%)
C L r , true
(ml/min)
Sulfamethoxazole 2.7 ±0.9 67.2 8.3
5-Hyd roxy su Ifamethoxazole 96.1 ± 23.7 40.3 161
Sulfamethoxazole-N-i-glucuronide 176 ±33 26.7 240
Nracetylsulfamethoxazole 35.2 ± 5.6 88.1 296
N4-acetyl-5-hydroxysulfamethoxazole 51.2 ±10.4 69.5 168
N-rhydroxysulfamethoxazole B a a
a Not stable in plasma.
Abbreviation: CLr = renal clearance.
The absorption half-life ( t ' / 2abs)  of sulfa- the compound is acetylated (88%); it decreases
methoxazole was 0.12 ± 0.14 hours, which was when it is oxidised at the 5-position (40%).
much shorter than that calculated for the metabo- Glucuronidation at the Ni-position reduces the
lites. The t '/2abs of N4 (2.3 ± 0.9 hours) was identical protein binding to 20%.
(P NS) to that of Sgluc (1.3 ± 1.4 hours). The
same was observed for the formation of the
hydroxy metabolites SOH (4.7 ± 5 .0  hours) and
N4SOH (4.5 ±  2.4 hours; p = NS).
The plasma elimination t '/2 varied between 9.6
and 1 1  hours (9.7 ± 1.3 hours) for the parent drug 
and metabolites. The t>/2 was slightly higher for
Sgluc (15.2 ± 5.3 hours; p = 0.0352). The elimina­
tion t1/-, derived from the renal excretion rate-timeM
curves for all compounds was identical to that of 
the N4~acetyl metabolite.
The mean residence times (MRT) of the meta­
bolites (20 to 25 hours) were higher than that o f the
parent drug (14.4 ±  2.2 hours; p = 0.0044). The 
intrinsic mean residence time (MRTi), defined as
MRTmeUiboIite-MRTparent drug, for N4 was 5.7 ± 1.9 
hours (p = 0.0006), for Sgluc was 9.6 ± 7.6 hours
Renal Clearance
(P NS); for N4SOH was 10.1 ± 3.0 hours (p
NS;NS); and for SOH was 20.6 ± 14.2 
p values compared with MRT-S).
The intrinsic MRTij of N4SOH, when it was as­
sumed to be formed from N4, was 3.9 ± 1.9 hours, 
which did not differ significantly from the MRTi of
N4-aceiylsulfamethoxazole (5.7 ±  1.9 hours).
The in vitro protein binding of sulfa- similar (161 vs 168 ml/min). The true renal clear- 
methoxazole is shown in table II. The protein bind- ance o f N 4 was similar to that of the Ni-glucuron- 
ing o f sulfamethoxazole (67.2%) increases when ide (296 vs 240 ml/min).
The main metabolite in urine was N4 (43.5 ±
5.6%), followed by sulfamethoxazole (14.4 ±
3.4%) and the Ni-glucuronide (9.8 ± 2.6%). The
percentages of N 4SOH (5.3 ± 1.0%) and SOH (3.0
±  1.0%) did not differ significantly (p = NS). Only
2.1 ±  0.9% of the N-hydroxylamine metabolite 
(N 4OH) was excreted. No difference was found be­
tween the fast and slow acetylators of sulfadimid­
ine concerning the percentage of metabolites of 
sulfamethoxazole.
The highest apparent renal clearance was
achieved with Sgluc with 176 ± 33 ml/min. When 
corrected for protein binding, the true renal clear­
ance was 240 ml/min. The renal clearance value of
SOH was 96.1 ±  23.7 ml/min, which was signifi­
cantly lower than that for the Ni-glucuronide 
(pcO.OOOl). The renal clearance value o f N4SOH
was 51.2 ±  10.4 ml/min and for N4 was 35.2 ±  5.6 
ml/min; these values were not significantly differ­
ent. When corrected for protein binding, the true 
renal clearance values of SOH and N4SOH were
Adis international Limited, All rights reserved. Clin. Drug Invest. 9 (1) 1995
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Sulfamethoxazole had the lowest apparent renal
clearance o f 2.7 ± 0.9 ml/min and a true renal clear­
ance of 8.3 ml/min (table III).
Discussion
Sulfamethoxazole is relatively well absorbed 
after oral administration. The percentage o f the 
dose excreted in the urine as parent drug and 
metabolites varied between 70 and 90% J1*"I41 The 
lag time (tiag) gives the sequence of appearance in 
plasma and an indication regarding the dissolution 
rate and the absorption rate of the parent drug and 
the apparent rate o f formation of the metabolites
(tiag metabolite - tiag parent).
The tmax is also a hybrid parameter, determined 
by the processes of absorption or formation and the 
intrinsic rate of elimination. Absorption of sul­
famethoxazole is readily completed as the tmax oc­
curs at 1 hour; those of the primary conjugates (N4- 
acetyl-, and Ni-glucuronide) occur at 5 to 7 hours. 
The oxidation to SOH and N4SOH proceeded at a
slower rate but for a longer period; tmax was
achieved at 10  hours.
The absorption half-life o f the metabolites is a 
hybrid of the rates of formation and elimination. 
Like the tmax, this variable demonstrated that the 
rates of formation of N4-acetylation and N i-  
glucuronidation were similar (p = 0.36), and as fast 
as the oxidation at the 5-position (p = 0.08). The 
Cmax and AUCo-00 values o f N4 were 10 times 
higher than those o f Sgluc. With equal absorp­
tion/formation rates and equal rates o f elimination 
by renal clearance, it may suggest that the maxi­
mum velocity of the capacity-limited process 
(V m ax) or the enzyme concentration of the N- 
acetylase(s) is 10  times higher than that of the
N 1 -glucuronyltransferase(s).
The apparent elimination half-life of all meta­
clearance of sulfamethoxazole contributes notice­
ably to the overall oral clearance. When the Va  of
m/ **
sulfamethoxazole was 10  hours, it was identical to 
that of the N4-acetyl metabolite. In the latter case 
the rate of acétylation of sulfamethoxazole governs 
the V/2 of both sulfamethoxazole and N4 (fig. 4). 
These differences were observed within one sub­
ject, but did not reach statistical significance in the 
whole group of volunteers. The metabolites SOH 
and Sgluc demonstrated very small AUC values; 
the plasma concentrations were 5 to 10 times the 
quantitation limit. In these cases, the parallelism of 
the renal excretion rate-time profiles demonstrated 
the similarity of the half-lives.
When the apparent plasma elimination half- 
lives of the metabolites are identical to that of the 
parent drug, the total body clearances of the meta­
bolites are higher and the intrinsic MRT values 
must be smaller than that of the parent drug, which 
indeed was the case (table I). Sulfamethoxazole is 
eliminated predominantly by metabolic conver­
sion into the metabolites, which in turn are elimi­
nated predominantly by renal excretion. The ace- 
tylator phenotype for sulfadimidine did not result 
in measurable differences in the percentage of the 
metabolite, nor in differences in the
lives.11 14,21 ] Thus, in the in vivo situation an ac- 
etylator phenotype for sulfamethoxazole cannot be 
distinguished.*24!
Sgluc and N4 showed the highest true renal 
clearance values as the result of glomerular filtra­
tion and active tubular secretion. All metabolites 
were excreted by active tubular secretion, as their 
renal clearance values exceeded the glomerular 
filtration rate. Furthermore, urine pH and urine 
flow have little effect on the renal clearance, and 
the renal clearance of N4 can be reduced by pro­
benecid comedication.112,’•'I The renal clearance
bolites was similar, as has been demonstrated many of the metabolites equalled their total body clear-
times previously for sulfamethoxazole and its acyl ance, indicating that they were not further metabo
metabolite.111_14' A slight variation in V/2 was ob- lised. The renal clearance of Sgluc was twice that
served between sulfamethoxazole and N4, the Va of the calculated total body clearance, which may
of sulfamethoxazole was 9 hours and that of N4 indicate that this glucuronide is synthesised in part 
was 10 hours. This occurred when the urine pH of by the human kidney, as previously reported for the 
the subject varied between pH 6 and 8 , and renal methoxysulfonamidesJ16' 18!
© Adis Internationai Limited. Ait rights reserved. Clin. Drug Invest. 9(1) 1995
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The electrophilic metabolite N4OI-I, which may 
be held responsible for the occurrence o f side 
effects,t5,251 was excreted for 2.1% of the dose in 
the urine. This means that only the free or un­
reacted N4OH was excreted and that the part caus­
ing side effects was not measured. When compar­
ing the pharmacokinetics of sulfamethoxazole 
between healthy volunteers and HIV-positive 
patients, discrepancies in metabolism may reveal a 
relationship with the occurrence of side effects in 
HIV-positive patients. If the percentage of N4OH 
excreted in the urine of HIV patients is less than 
that in healthy volunteers, it must be guaranteed 
that this is not the result of alterations in the C-oxi- 
dation, N4-acetylation and Ni-glucuronidation.
This work is now under investigation.
Conclusion
In conclusion, sulfamethoxazole is well ab­
sorbed from the gastrointestinal tract and biotrans­
formed to 5 metabolites. It is oxidised and conju­
gated by acétylation and glucuronidation. The 
pharmacokinetics of the N 1 -glucuronide have been 
reported for the first time. The parent drug was 
eliminated mainly by metabolism, while the meta­
bolites were eliminated mainly by renal excretion, 
resulting in comparable apparent half-lives.
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